Atrial Fibrillation in Primary Aldosteronism

Chien-Ting Pan; Cheng-Hsuan Tsai; Zheng-Wei Chen; Yi-Yao Chang; Vin-Cent Wu; Chi-Sheng Hung; Yen-Hung Lin; the TAIPAI Study Group

doi:10.1055/a-1141-5989

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2020; 52(06): 357-365
DOI: 10.1055/a-1141-5989

Review

Atrial Fibrillation in Primary Aldosteronism

Chien-Ting Pan

¹Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan

²Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

,

Cheng-Hsuan Tsai

²Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

³Department of Internal Medicine, National Taiwan University Hospital Jin-Shan Branch, New Taipei City, Taiwan

,

Zheng-Wei Chen

¹Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan

²Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

,

Yi-Yao Chang

⁴Cardiology Division of Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan

,

Vin-Cent Wu

⁵Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

,

Chi-Sheng Hung

²Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

⁶Cardiovascular Center, National Taiwan University Hospital, Taipei, Taiwan

,

Yen-Hung Lin

²Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

⁶Cardiovascular Center, National Taiwan University Hospital, Taipei, Taiwan

,

the TAIPAI Study Group

› Author Affiliations

Abstract

Primary aldosteronism (PA) is the most common cause of secondary hypertension. Increasing evidence has demonstrated an increased cardiovascular risk in patients with PA compared to those with essential hypertension (EH), including atrial fibrillation (AF), the most prevalent arrhythmia among adults that is associated with an elevated risk of subsequent cerebro-cardiovascular adverse events. The mechanisms of increased prevalence of AF in PA patients are complex. Excessive aldosterone production is regarded to be a key component in the pathogenesis of AF, in addition to arterial hypertension and electrolyte imbalance. In addition, several translational and clinical studies have reported that structural remodeling with atrial fibrosis and electrical remodeling with arrhythmogenicity induced by an excess of aldosterone also play major roles in AF genesis. Clinical studies from several registries and meta-analysis have reported an increased prevalence and risk of AF in PA patients compared to EH patients. Recent trials have further demonstrated a reduction in the risk of new-onset atrial fibrillation (NOAF) after adrenalectomy, while the results of medical treatment with mineralocorticoid receptor antagonists (MRAs) have been inconsistent. This review outlines the current evidence of the relationship between PA and AF, and highlights recent progress in the management of PA with regards to the development of AF.

Key words

atrial fibrillation - primary aldosteronism - aldosterone - atrial remodeling

Full Text

References

References
1 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
2 Milliez P, Girerd X, Plouin PF. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
3 Monticone S, D’Ascenzo F, Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 41-50
4 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 2016; 50: e1-e88
5 Born-Frontsberg E, Reincke M, Rump LC. et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s Registry. J Clin Endocrinol Metab 2009; 94: 1125-1130
6 Staerk L, Sherer JA, Ko D. et al. Atrial fibrillation: epidemiology. pathophysiology, and clinical outcomes. Circul Res 2017; 120: 1501-1517
7 Hirsh BJ, Copeland-Halperin RS, Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. J Am Coll Cardiol 2015; 65: 2239-2251
8 Gravez B, Tarjus A, Jaisser F. Mineralocorticoid receptor and cardiac arrhythmia. Clin Exp Pharmacol Physiol 2013; 40: 910-915
9 Haissaguerre M, Jais P, Shah DC. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Eng J Med 1998; 339: 659-666
10 Hove-Madsen L, Llach A, Bayes-Genis A. et al. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation 2004; 110: 1358-1363
11 Burstein B, Libby E, Calderone A. et al. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation 2008; 117: 1630-1641
12 Rossi GP, Sacchetto A, Visentin P. et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27: 1039-1045
13 Kozakova M, Buralli S, Palombo C. et al. Myocardial ultrasonic backscatter in hypertension: relation to aldosterone and endothelin. Hypertension 2003; 41: 230-236
14 Fiebeler A, Schmidt F, Muller DN. et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 2001; 37 787-793
15 Keidar S, Kaplan M, Pavlotzky E. et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004; 109: 2213-2220
16 Sun Y, Zhang J, Lu L. et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161: 1773-1781
17 Yoshida K, Kim-Mitsuyama S, Wake R. et al. Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. Hypertens Res 2005; 28: 447-455
18 Shen JZ, Morgan J, Tesch GH. et al. Cardiac tissue injury and remodeling is dependent upon mr regulation of activation pathways in cardiac tissue macrophages. Endocrinology 2016; 157: 3213-3223
19 Usher MG, Duan SZ, Ivaschenko CY. et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010; 120: 3350-3364
20 Oestreicher EM, Martinez-Vasquez D, Stone JR. et al. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation 2003; 108: 2517-2523
21 Desmouliere A, Geinoz A, Gabbiani F. et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122: 103-111
22 Baum J, Duffy HS. Fibroblasts and myofibroblasts: what are we talking about?. J Cardiovasc Pharmacol 2011; 57: 376-379
23 Yang Y, Chen S, Tao L. et al. Inhibitory effects of oxymatrine on transdifferentiation of neonatal rat cardiac fibroblasts to myofibroblasts induced by aldosterone via Keap1/Nrf2 signaling pathways in vitro. Med Sci Monit 2019; 25: 5375-5388
24 Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997; 35: 138-147
25 Reil JC, Hohl M, Selejan S. et al. Aldosterone promotes atrial fibrillation. Eur Heart J 2012; 33: 2098-2108
26 Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhyth Electrophysiol 2008; 1: 62-73
27 Heijman J, Voigt N, Nattel S. et al. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res 2014; 114: 1483-1499
28 Lammers C, Dartsch T, Brandt MC. et al. Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat. Cell Physiol Biochem 2012; 29: 833-840
29 Agarwal YK, Aronow WS, Levy JA. et al. Association of interatrial block with development of atrial fibrillation. Am J Cardiol 2003; 91: 882
30 Magnani JW, Johnson VM, Sullivan LM. et al. P wave duration and risk of longitudinal atrial fibrillation in persons >/= 60 years old (from the Framingham Heart Study). Am J Cardiol 2011; 107: 917-921 e911
31 Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP. et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005; 111: 3025-3033
32 Gomez AM, Rueda A, Sainte-Marie Y. et al. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation 2009; 119: 2179-2187
33 Tsai CT, Chiang FT, Tseng CD. et al. Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 2010; 55: 758-770
34 Seidel E, Schewe J, Scholl UI. Genetic causes of primary aldosteronism. Exp Mol Med 2019; 51: 131
35 Amin AS, Wilde AAM. Inheritable potassium channel diseases. In cardiac electrophysiology: from cell to bedside. Amsterdam: Elsevier, Inc; 2018: 494-503
36 Jabbari J, Olesen MS, Holst AG. et al. Common polymorphisms in KCNJ5 [corrected] are associated with early-onset lone atrial fibrillation in Caucasians. Cardiology 2011; 118: 116-120
37 Yamada N, Asano Y, Fujita M. et al. Mutant KCNJ3 and KCNJ5 potassium channels as novel molecular targets in bradyarrhythmias and atrial fibrillation. Circulation 2019; 139: 2157-2169
38 Cramariuc D, Gerdts E. Epidemiology of left ventricular hypertrophy in hypertension: implications for the clinic. Expert Rev Cardiovasc Ther 2016; 14: 915-926
39 Nadruz W, Shah AM, Solomon SD. Diastolic dysfunction and hypertension. Med Clin North Am 2017; 101: 7-17
40 Lau DH, Nattel S, Kalman JM. et al. Modifiable risk factors and atrial fibrillation. Circulation 2017; 136: 583-596
41 Rosenberg MA, Manning WJ. Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal. Circulation 2012; 126: 2353-2362
42 Kistler PM, Sanders P, Dodic M. et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. Eur Heart J 2006; 27: 3045-3056
43 Vaziri SM, Larson MG, Lauer MS. et al. Influence of blood pressure on left atrial size. The framingham heart study. Hypertension 1995; 25: 1155-1160
44 Henry WL, Morganroth J, Pearlman AS. et al. Relation between echocardiographically determined left atrial size and atrial fibrillation. Circulation 1976; 53: 273-279
45 Kannel WB, Wolf PA, Benjamin EJ. et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82 2n-9n
46 Al-Aloul B, Li JM, Benditt D. et al. Atrial fibrillation associated with hypokalemia due to primary hyperaldosteronism (Conn's syndrome). Pacing Clin Electrophysiol 2006; 29: 1303-1305
47 Watson T, Karthikeyan VJ, Lip GY. et al. Atrial fibrillation in primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2009; 10: 190-194
48 Krijthe BP, Heeringa J, Kors JA. et al Serum potassium levels and the risk of atrial fibrillation: the Rotterdam Study. Int J Cardiol 2013; 168: 5411-5415
49 Auer J, Weber T, Berent R. et al. Serum potassium level and risk of postoperative atrial fibrillation in patients undergoing cardiac surgery. J Am Coll Cardiol 2004; 44: 938-939
50 Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhyth Electrophysiol 2017; 10 pii e004667
51 Catena C, Colussi G, Nadalini E. et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85
52 Savard S, Amar L, Plouin PF. et al. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013; 62: 331-336
53 Mulatero P, Monticone S, Bertello C. et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 2013; 98: 4826-4833
54 Ohno Y, Sone M, Inagaki N. et al. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: a multicenter study in Japan. Hypertension 2018; 71: 530-537
55 Mourtzinis G, Ebrahimi A, Gustafsson H. et al. Aldosterone to renin ratio as a screening instrument for primary aldosteronism in a middle-aged population with atrial fibrillation. Horm Metab Res 2017; 49: 831-837
56 Mourtzinis G, Adamsson Eryd S, Rosengren A. et al. Primary aldosteronism and thyroid disorders in atrial fibrillation: a Swedish nationwide case-control study.. Eur J Prev Cardiol 2018; 25: 694-701
57 Seccia TM, Letizia C, Muiesan ML. et al. Atrial fibrillation as presenting sign of primary aldosteronism: results of the prospective appraisal on the prevalence of primary aldosteronism in hypertensive (PAPPHY) study. J Hypertens 2020; 38: 332-339
58 Hoit BD. Left atrial size and function: role in prognosis. J Am Coll Cardiol 2014; 63: 493-505
59 Nagueh SF, Smiseth OA, Appleton CP. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr 2016; 29: 277-314
60 Yang Y, Zhu LM, Xu JZ. et al. Comparison of left ventricular structure and function in primary aldosteronism and essential hypertension by echocardiography. Hypertens Res 2017; 40: 243-250
61 Chen ZW, Huang KC, Lee JK. et al. Aldosterone induces left ventricular subclinical systolic dysfunction: a strain imaging study. J Hypertens 2018; 36: 353-360
62 Wang D, Xu JZ, Chen X. et al. Left atrial myocardial dysfunction in patients with primary aldosteronism as assessed by speckle-tracking echocardiography. J Hypertens 2019; 37: 2032-2040
63 Stowasser M, Sharman J, Leano R. et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90: 5070-5076
64 Catena C, Colussi G, Lapenna R. et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918
65 Muiesan ML, Salvetti M, Paini A. et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529-534
66 Cesari M, Letizia C, Angeli P. et al. Cardiac remodeling in patients with primary and secondary aldosteronism: a tissue doppler study. Circ Cardiovasc Imaging 2016; 9 e004815
67 Lin YH, Huang KH, Lee JK. et al. Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy. J Renin Angiotensin Aldosterone Syst 2011; 12: 48-53
68 Hung CS, Ho YL, Chang YY. et al. Twenty-four-hour urinary aldosterone predicts inappropriate left ventricular mass index in patients with primary aldosteronism. Sci World J. 2013: 294594
69 Chang YY, Lee HH, Hung CS. et al. Association between urine aldosterone and diastolic function in patients with primary aldosteronism and essential hypertension. Clin Biochem 2014; 47: 1329-1332
70 Kontak AC, Wang Z, Arbique D. et al. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab 2010; 95: 4756-4761
71 Khan AA, Lip GYH, Shantsila A. Heart rate variability in atrial fibrillation: the balance between sympathetic and parasympathetic nervous system. Eur J Clin Invest 2019; 49: e13174
72 Perkiomaki J, Ukkola O, Kiviniemi A. et al. Heart rate variability findings as a predictor of atrial fibrillation in middle-aged population. J Cardiovasc Electrophysiol 2014; 25: 719-724
73 Friedman HS. Heart rate variability in atrial fibrillation related to left atrial size. Am J Cardiol 2004; 93: 705-709
74 Agarwal SK, Norby FL, Whitsel EA. et al. Cardiac autonomic dysfunction and incidence of atrial fibrillation: results from 20 years follow-up. J Am Coll Cardiol 2017; 69: 291-299
75 Veglio F, Melchio R, Rabbia F. et al. Spectral characteristics of heart rate and blood pressure variability in primary aldosteronism. Am J Hypertens 1995; 8 479-486
76 Lin YH, Wu VC, Lo MT. et al. Reversible heart rhythm complexity impairment in patients with primary aldosteronism. Sci Rep 2015; 5: 11249
77 Dzeshka MS, Shantsila A, Shantsila E. et al. Atrial fibrillation and hypertension. Hypertension 2017; 70: 854-861
78 Reincke M, Fischer E, Gerum S. et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension 2012; 60: 618-624
79 Liao CW, Lin LY, Hung CS. et al. Time course and factors predicting arterial stiffness reversal in patients with aldosterone-producing adenoma after adrenalectomy: prospective study of 102 patients. Sci Rep 2016; 6: 20862
80 Rossi GP, Maiolino G, Flego A. et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension 2018; 71: 585-591
81 Hundemer GL, Curhan GC, Yozamp N. et al. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol 2018; 3: 768-774
82 Pan CT, Liao CW, Tsai CH. et al. Influence of different treatment strategies on new-onset atrial fibrillation among patients with primary aldosteronism: a nationwide longitudinal cohort-based study. J Am Heart Assoc 2020; 9: e013699
83 Hundemer GL, Curhan GC, Yozamp N. et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6: 51-59
84 Rossi GP, Cesari M, Cuspidi C. et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62: 62-69
85 Rossi GP, Sacchetto A, Pavan E. et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997; 95: 1471-1478
86 Indra T, Holaj R, Štrauch B. et al. Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2015; 16: 1109-1117
87 Lin YH, Huang KH, Lee JK. et al. Factors influencing left ventricular mass regression in patients with primary aldosteronism post adrenalectomy. J Renin Angiotensin Aldosterone Syst 2011; 12: 48-53
88 Lin YH, Lee HH, Liu KL. et al. Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy. Surgery 2011; 150: 526-533
89 Chang YY, Liao CW, Tsai CH. et al. Left ventricular dysfunction in patients with primary aldosteronism: a propensity score-matching follow-up study with tissue doppler imaging. J Am Heart Assoc 2019; 8: e013263
90 Choi M, Scholl UI, Yue P. et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-772
91 Gomez-Sanchez CE, Oki K. Minireview: potassium channels and aldosterone dysregulation: is primary aldosteronism a potassium channelopathy?. Endocrinology 2014; 155: 47-55
92 Williams TA, Monticone S, Mulatero P. KCNJ5 mutations are the most frequent genetic alteration in primary aldosteronism. Hypertension 2015; 65: 507-509
93 Rossi GP, Cesari M, Letizia C. et al. KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism. J Hypertens 2014; 32: 1514-1521
94 Lenzini L, Rossitto G, Maiolino G. et al. A meta-analysis of somatic KCNJ5 K(+) channel mutations in 1636 patients with an aldosterone-producing adenoma. J Clin Endocrinol Metab 2015; 100: E1089-E1095
95 Wu VC, Huang KH, Peng KY. et al. Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population. Sci Rep 2015; 5: 11396
96 Fujimoto K, Honjo S, Tatsuoka H. et al. Primary aldosteronism associated with subclinical Cushing syndrome. J Endocrinol Invest 2013; 36: 564-567
97 Spath M, Korovkin S, Antke C. et al. Aldosterone- and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism. Eur J Endocrinol 2011; 164: 447-455
98 Tang L, Li X, Wang B. et al. Clinical characteristics of aldosterone- and cortisol-coproducing adrenal adenoma in primary aldosteronism. 2018 4920841.
99 Kamenicky P, Redheuil A, Roux C. et al. Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study. J Clin Endocrinol Metab 2014; 99: E2144-E2153
100 van der Hooft CS, Heeringa J, Brusselle GG. et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006; 166: 1016-1020
101 Liu SY, Chu CC, Tsui TK. et al. Aldosterone-producing adenoma in primary aldosteronism: CT-guided radiofrequency ablation-long-term results and recurrence rate. Radiology 2016; 281: 625-634
102 Amar L, Azizi M, Menard J. et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010; 56: 831-838
103 Morimoto R, Omata K, Ito S. et al. Progress in the management of primary aldosteronism. Am J Hypertens 2018; 31: 522-531